WO2023004690A1 - Antioxidant nutrition composition capsule - Google Patents
Antioxidant nutrition composition capsule Download PDFInfo
- Publication number
- WO2023004690A1 WO2023004690A1 PCT/CN2021/109295 CN2021109295W WO2023004690A1 WO 2023004690 A1 WO2023004690 A1 WO 2023004690A1 CN 2021109295 W CN2021109295 W CN 2021109295W WO 2023004690 A1 WO2023004690 A1 WO 2023004690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- antioxidant
- coenzyme
- combination
- metabolism
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 60
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 57
- 239000002775 capsule Substances 0.000 title claims abstract description 43
- 235000016709 nutrition Nutrition 0.000 title claims description 42
- 230000035764 nutrition Effects 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 64
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 60
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 56
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 35
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 34
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 33
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 33
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 30
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 30
- 239000011709 vitamin E Substances 0.000 claims abstract description 30
- 229940046009 vitamin E Drugs 0.000 claims abstract description 30
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 29
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 29
- 239000011718 vitamin C Substances 0.000 claims abstract description 29
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 25
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 25
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 44
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 30
- 229930182817 methionine Natural products 0.000 claims description 26
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 26
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 25
- 229940011671 vitamin b6 Drugs 0.000 claims description 22
- 229930003779 Vitamin B12 Natural products 0.000 claims description 19
- 235000019163 vitamin B12 Nutrition 0.000 claims description 19
- 239000011715 vitamin B12 Substances 0.000 claims description 19
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 18
- 235000019158 vitamin B6 Nutrition 0.000 claims description 18
- 239000011726 vitamin B6 Substances 0.000 claims description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 15
- 235000019152 folic acid Nutrition 0.000 claims description 15
- 239000011724 folic acid Substances 0.000 claims description 15
- 229960000304 folic acid Drugs 0.000 claims description 15
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229960003581 pyridoxal Drugs 0.000 claims description 4
- 235000008164 pyridoxal Nutrition 0.000 claims description 4
- 239000011674 pyridoxal Substances 0.000 claims description 4
- 235000008151 pyridoxamine Nutrition 0.000 claims description 4
- 239000011699 pyridoxamine Substances 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 125000002640 tocopherol group Chemical group 0.000 claims description 4
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 235000013736 caramel Nutrition 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 description 22
- 230000003064 anti-oxidating effect Effects 0.000 description 21
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 21
- 150000003254 radicals Chemical class 0.000 description 21
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 230000037149 energy metabolism Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000032683 aging Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 10
- 239000005515 coenzyme Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000003712 anti-aging effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000037353 metabolic pathway Effects 0.000 description 6
- 230000008558 metabolic pathway by substance Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000003225 hyperhomocysteinemia Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000005460 tetrahydrofolate Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940082632 vitamin b12 and folic acid Drugs 0.000 description 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 2
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 2
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 2
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 2
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 102100029562 Nicotinamide riboside kinase 1 Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 108700040121 Protein Methyltransferases Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 2
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000027829 mitochondrial depolarization Effects 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ZHKQAQKGVKBJPP-YUZLPWPTSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZHKQAQKGVKBJPP-YUZLPWPTSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AUFGTPPARQZWDO-YUZLPWPTSA-N 10-formyltetrahydrofolate Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YUZLPWPTSA-N 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000633302 Homo sapiens Nicotinamide riboside kinase 1 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 101100133505 Mus musculus Nmnat1 gene Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 1
- 101710134519 Nicotinamide riboside kinase 1 Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 108010021066 nicotinamide riboside kinase Proteins 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000037050 permeability transition Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UFQIEPASVGNVKU-UHFFFAOYSA-N phosphono dihydrogen phosphate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.OP(O)(=O)OP(O)(O)=O UFQIEPASVGNVKU-UHFFFAOYSA-N 0.000 description 1
- XENHFSZRMFXQBS-UHFFFAOYSA-N phosphoric acid;pyridine-3-carboxamide Chemical compound OP(O)(O)=O.NC(=O)C1=CC=CN=C1 XENHFSZRMFXQBS-UHFFFAOYSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000005234 proximal tubule cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- the invention relates to the technical field of health care products, in particular to an antioxidant nutritional combination capsule.
- the tricarboxylic acid cycle is the hub of energy metabolism. It is carried out in the mitochondria of the cells of the whole body. Through the tricarboxylic acid cycle, more energy is generated to maintain the normal physiological and biochemical conditions of the human body. To maintain the normal functioning of the human body.
- oxidative substances will be produced at the same time. Most of these oxidative substances are electrons generated in metabolism, which form oxidative free radicals in tissues, causing oxidative damage to tissue cells, resulting in denaturation and death of human cell tissues. Ageing.
- antioxidants to fight against this kind of oxidative free radicals, to protect the body's tissue damage caused by oxidative free radicals produced in energy metabolism at any time, and to prevent the body from premature aging and aging caused by oxidative damage. Thereby prolonging the life of the human body.
- antioxidant free radicals are independent antioxidant ingredients. Although these ingredients play a certain role in the antioxidant free radicals, they are beneficial to maintaining the health of the body; Antioxidants contain a relatively single component, and their antioxidant effects are limited. They cannot better meet the antioxidant needs of the whole body's cells and tissues, and cannot compensate for the damage caused by oxidative free radicals produced by various tissue cells throughout the body, so they cannot be better. Eliminate the health hazards generated in the energy metabolism of the human body.
- the invention provides an anti-oxidation nutrition combination capsule, which contains more nutrients needed in the energy metabolism of the human body, ensures the normal energy and substance metabolism of the human body, and has obvious anti-oxidation, anti-aging, and maintains the healthy state of human body functions. extend your life.
- an antioxidant nutritional combination capsule provided by the present invention contains 150-900 mg of ⁇ -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300mg of lipoic acid, 0.4-5mg of vitamin B6, 10-100ug of vitamin B12 and 20-200ug of folic acid; the average grain weight of the antioxidant nutrition combination capsule is 0.5g, and the content of the antioxidant nutrition combination capsule is on average The volume is 0.68 mL.
- the vitamin B6, the vitamin B12, and the folic acid cooperate with each other to promote the circulation of methionine.
- the vitamin E is a fat-soluble vitamin
- the hydrolyzate of the vitamin E is tocopherol
- the vitamin C is a polyhydroxy compound
- the vitamin B6 includes pyridoxine, pyridoxal and Pyridoxamine.
- each capsule of the antioxidant nutrition combination also contains gelatin, glycerin, water and caramel coloring.
- each capsule of the antioxidant nutrition combination contains 200mg of ⁇ -nicotinamide mononucleotide, 40mg of coenzyme Q10, 50mg of vitamin E, 100mg of vitamin C, 50mg of lipoic acid, 5mg of vitamin B6, 100ug of vitamin B12 and 200ug of folic acid.
- the ⁇ -nicotinamide mononucleotide, the coenzyme Q10, the vitamin E, the vitamin C and the lipoic acid cooperate with each other and act synergistically to form an antioxidant combination.
- the vitamin E, the vitamin C and the lipoic acid cooperate with the coenzyme Q10 to achieve a combined antioxidant effect.
- the embodiment of the present invention provides an antioxidant nutritional combination capsule, which combines various antioxidants such as ⁇ -nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid, etc., and synergistically enhances anti-oxidation and anti-aging
- the effect is to protect the tissue cells of the whole body, so that the tissue cells of the whole body can maintain a healthy and young state and make life longer; at the same time, it is designed for the defects of the Chinese diet characteristics, preventing energy and material metabolism disorders caused by the lack of certain nutrients.
- the combination of vitamin B6, vitamin B12 and folic acid can promote the metabolism of methionine and realize the hub of human energy metabolism and material metabolism. It can effectively prevent arteriosclerosis and make various metabolisms of the human body go on healthily. Oxidation, anti-aging and other effects can protect the heart and vital organs of the body, and can maintain the health of human body functions.
- An antioxidant nutritional combination capsule contained 150-900 mg of ⁇ -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50 ⁇ 300mg of lipoic acid, 0.4 ⁇ 5mg of vitamin B6, 10 ⁇ 100ug of vitamin B12 and 20 ⁇ 200ug of folic acid; the average grain weight of the antioxidant nutrition combination capsule is 0.5g, and the average volume of the content of the antioxidant nutrition combination capsule is 0.68mL.
- vitamin B6, vitamin B12, and folic acid cooperate with each other to promote the circulation of methionine.
- Vitamin E is a fat-soluble vitamin
- the hydrolysis product of vitamin E is tocopherol
- vitamin C is a polyhydroxy compound
- vitamin B6 includes pyridoxine, pyridoxal and pyridoxamine.
- each capsule of an antioxidant nutritional combination provided by the embodiment of the present invention also contains gelatin, glycerin, water and caramel coloring.
- each antioxidant nutrition combination capsule contains 200mg of ⁇ -nicotinamide mononucleotide, 40mg of coenzyme Q10, 50mg of vitamin E, 100mg of vitamin C, 50mg of lipoic acid, 5mg of vitamin B6, and 100ug of vitamin B12 and 200ug folic acid, the anti-oxidation nutritional combination capsule with this ratio has the best anti-oxidation effect.
- ⁇ -nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C and lipoic acid cooperate with each other and act synergistically to form an antioxidant combination.
- Vitamin E, vitamin C and lipoic acid synergize with coenzyme Q10 to achieve a joint antioxidant effect.
- the ⁇ -nicotinamide mononucleotide (Nicotinamide mononucleotide, NMN) used in the anti-oxidation nutritional combination capsule plays an important role in the energy generation of human cells, and it participates in the intracellular NAD+ (also known as nicotinamide Adenine dinucleotide, an important coenzyme for cellular energy conversion), is the precursor of NAD+.
- NAD+ also known as nicotinamide Adenine dinucleotide, an important coenzyme for cellular energy conversion
- artificial supplementation of NMN can greatly increase the level of NAD+, and has a good therapeutic and repair effect on cardiovascular and cerebrovascular diseases, neurodegenerative diseases, and aging degenerative diseases. This is also the core of NMN to reverse aging and prolong life.
- NMN can also protect and repair islet function, increase insulin secretion, and prevent and treat metabolic diseases such as diabetes and obesity by participating in and regulating the endocrine of the body; at the same time, it can also prevent and treat obesity, protect the heart immune In ischemia-reperfusion injury, it has a certain preventive and therapeutic effect on retinal degenerative diseases, type 2 diabetes, and cerebral hemorrhage. Regular intake of NMN can effectively increase the content of NAD+ in the body, thereby helping humans repair DNA damage, prevent degenerative diseases, and delay aging.
- the coenzyme Q10 used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention can not only provide power to the heart, but also has excellent anti-oxidation and free radical scavenging functions, can prevent lipid peroxidation in blood vessel walls, and prevent atherosclerosis Hardened, and without any side effects.
- the vitamin E (Vitamin E) it uses is a fat-soluble vitamin, and its hydrolyzed product is tocopherol, which is one of the most important antioxidants.
- Vitamin E can promote reproductive function, protect T lymphocytes, protect red blood cells, resist free radical oxidation, inhibit platelet aggregation, thereby reducing the risk of myocardial infarction and cerebral infarction; It has a good curative effect; it can inhibit the lipid peroxide reaction in the lens of the eye, expand the peripheral blood vessels, and improve blood circulation; it can effectively fight against free radicals, inhibit the generation of lipid peroxide, and remove chloasma; inhibit tyrosinase
- the activity of melanin, thereby reducing the production of melanin; the esterified form of vitamin E can also eliminate the excessive oxygen free radicals caused by external factors such as ultraviolet rays and air pollution, so as to delay photoaging, prevent sunburn and inhibit the formation of sun erythema, etc. effect.
- the structure of the vitamin C used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention is similar to that of glucose, and is a polyhydroxy compound.
- Vitamin C has a strong reducing property and is easily oxidized to dehydrovitamin C, but the reaction is reversible, and ascorbic acid and dehydroascorbic acid have the same physiological function.
- Vitamin C is for the formation of antibodies and collagen, tissue repair (including certain redox effects), metabolism of phenylalanine, tyrosine, and folic acid, utilization of iron and carbohydrates, synthesis of fat and protein, maintenance of immune function, hydroxyl Antioxidant 5-hydroxytryptamine is necessary to maintain the integrity of blood vessels and promote the absorption of non-heme iron.
- vitamin C also has anti-oxidation, anti-free radicals, and inhibits the formation of tyrosinase, so as to achieve the effect of whitening and lightening spots.
- the antioxidant effect of vitamin C can be understood as a "protective effect”.
- the strong antioxidant effect of vitamin C can also be used to inhibit free radicals from oxidative damage to the human body, thereby preventing the invasion of tumors and cancers.
- the lipoic acid used in the antioxidant nutritional combination capsule provided by the embodiment of the present invention is a coenzyme existing in mitochondria, similar to vitamins, and can eliminate free radicals that lead to accelerated aging and disease.
- Alpha lipoic acid enters the cells after being absorbed by the intestines in the body, and has both fat-soluble and water-soluble properties.
- As a coenzyme it plays a role in two key oxidative decarboxylation reactions, that is, in the pyruvate dehydrogenase complex and the ⁇ -ketoglutarate dehydrogenase complex, catalyzing the generation and transfer of acyl groups.
- ⁇ -lipoic acid contains a disulfide five-membered ring structure, has a high electron density, has significant electrophilicity and the ability to react with free radicals, so it has antioxidant properties, and has extremely high health care functions and medical value (such as anti fatty liver and lowering of plasma cholesterol).
- the sulfhydryl group of lipoic acid is easy to undergo redox reaction, so it can protect the sulfhydryl enzyme from the poison of heavy metal ions. After lipoic acid enters the human body, it is easily reduced to dihydrolipoic acid, both of which can promote the regeneration of vitamin C and vitamin E, and play an antioxidant role.
- the drug can also increase intracellular glutathione and coenzyme Q10 and can chelate certain metal ions.
- the vitamin B6 used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention includes pyridoxine, pyridoxal and pyridoxamine, and is a water-soluble vitamin that is easily destroyed by light or alkali and is not resistant to high temperature. Participate in protein synthesis and catabolism, participate in all amino acid metabolism; participate in protein synthesis and catabolism, participate in all amino acid metabolism, especially the metabolism of methionine; an important substance to maintain body functions.
- the vitamin B12 used in it can participate in the synthesis of methionine, thymine, etc., promote the development and maturation of red blood cells, have the function of activating amino acids and promote the biosynthesis of nucleic acids, and can promote the synthesis and metabolism of proteins, so that fatty acids, carbohydrates, and proteins are absorbed by the body.
- Appropriate use it is an indispensable vitamin for the healthy function of the nervous system, participates in the formation of a lipoprotein in the nerve tissue, and maintains the metabolism and function of the nerve myelin sheath.
- ⁇ -nicotinamide mononucleotide coenzyme Q10, vitamin E, vitamin C and lipoic acid cooperate with each other and synergistically form an antioxidant combination, which has a special health care effect.
- ⁇ -nicotinamide mononucleotide (Nicotinamide mononucleotide, NMN) plays an important role in the energy generation of human cells. synthesis. NAD+, also known as coenzyme I, the full name of nicotinamide adenine dinucleotide, also known as nicotinic acid diphosphate, exists in every cell and participates in thousands of reactions, participating in all aspects of human metabolism, and is a key coenzyme.
- the NAD+ level in the human body is gradually declining.
- the NAD+ level in the human body is only 25% of the childhood level, and after the age of 80, it drops to 6.25% of the infant level.
- the decline of NAD+ It will lead to the reduction of mitochondrial activity, accelerate the aging of mitochondria, cells and even the whole body, and gradually enter a vicious circle. This is the reason why we get old and develop diseases.
- NAD+ has a large molecular weight and cannot be produced directly by oral administration, but since ⁇ -nicotinamide mononucleotide (NMN) is the precursor of NAD+, NAD+ content can be increased by oral supplementation of NMN, thereby bypassing the NAMPT rate-limiting enzyme It is the best and most scientific way to replenish NAD+ in the body quickly.
- NMN ⁇ -nicotinamide mononucleotide
- NMN is an intermediate in the salvage synthesis pathway of nicotinamide adenine dinucleotide (NAD+) in mammals.
- NMN nicotinamide mononucleotide
- Nampt nicotinamide phosphate ribose transferase
- Nmnat Nicotinamide mononucleotide adenosine transferase
- Extracellular NMN needs to be dephosphorylated and transformed into nicotinamide riboside (NR) to enter the interior of liver cells.
- NR is phosphorylated by nicotinamide riboside kinase 1 (Nicotinamide riboside kinase, NRK1) to generate NMN, followed by the combination of NMN and ATP to generate NAD+.
- NMN exerts its physiological functions by converting into NAD+ in the human body, such as activating NAD+ substrate-dependent enzyme Sirt1 (histone deacetylase, also known as sirtuin), regulating cell survival and death, maintaining redox state, etc.
- Regular intake of NMN can effectively increase the content of NAD+ in the body, thereby helping humans repair DNA damage, prevent degenerative diseases, and delay aging. This is also the core mechanism for NMN to reverse aging and prolong life.
- the tricarboxylic acid cycle (TCA cycle) is a metabolic pathway ubiquitous in aerobic organisms. It is distributed in the cytoplasm in prokaryotes and in the mitochondria in eukaryotes. Because several main intermediate metabolites in this cycle are organic acids containing three carboxyl groups, such as citric acid, it is called tricarboxylic acid cycle, also known as citric acid cycle or TCA cycle.
- the tricarboxylic acid cycle is the final metabolic pathway of the three major nutrients (sugars, lipids, and amino acids), and it is also the hub of the metabolic connection of sugars, lipids, and amino acids.
- Electrons are a kind of oxidant, that is, oxygen free radicals. Free radicals are normal metabolic products of cells. Generally, the production of free radicals and Clearance is in a state of dynamic balance. Once the balance is broken, the accumulation of free radicals in the body can cause oxidative stress, leading to the peroxidation of DNA, lipids and proteins, causing mitochondrial dysfunction and apoptosis. Oxidative stress and mitochondrial dysfunction are mutually causal, forming a vicious circle, which leads to the degeneration and aging of human metabolic tissues.
- Coenzyme Q10 is the only naturally occurring, renewable, fat-soluble antioxidant in the human body. There are two forms of coenzyme Q10 in the body, including the oxidized form and the reduced form. The two forms can be converted into each other in the body, but only the reduced form of coenzyme Q10 can play an antioxidant role in the body.
- the antioxidant activity of coenzyme Q10 is mainly reflected in scavenging free radicals, synergistic effect with other antioxidant substances, anti-apoptosis and stabilizing cell membrane. Coenzyme Q10 can scavenge free radicals in the body, reduce oxidative stress, and improve mitochondrial dysfunction through the conversion of redox structure.
- the mechanism of action of Coenzyme Q10 in inhibiting apoptosis may include: 1 Protecting mitochondrial DNA, Coenzyme Q10 can scavenge oxygen free radicals, reduce oxidative stress, prevent mitochondrial DNA mutation caused by peroxidative damage, maintain the integrity of mitochondrial respiratory chain, reduce cell Apoptosis; 2Coenzyme Q10 can increase the production efficiency of mitochondrial ATP, promote cell metabolism and growth, and slow down cell apoptosis; 3Inhibit mitochondrial depolarization: Coenzyme Q10 can prevent mitochondrial depolarization by inhibiting the opening of mitochondrial permeability transition channels Polarization, thereby inhibiting the release of cytochrome C and the activation of procaspase-9 (procaspase-9), inhibiting the activation of mitochondria-dependent apoptotic pathways, and exerting an anti-apoptotic effect; 4 inhibiting reactive oxygen species (ROS) related Apoptotic pathway: In renal proximal tubule cells, coenzyme Q10 significantly inhibited nicotine-induced RO
- the vitamin E, vitamin C and lipoic acid in the antioxidant nutritional combination capsule of the embodiment of the present invention cooperate with coenzyme Q10 to realize the combined antioxidant effect.
- lipoic acid is easily reduced to dihydrolipoic acid after entering the human body, and the cooperation of lipoic acid and coenzyme Q10 can promote the regeneration of vitamin C and vitamin E, and play an antioxidant role.
- the antioxidant nutrition combination capsule of the embodiment of the present invention can also increase intracellular glutathione and coenzyme Q10, and can chelate certain metal ions.
- Several antioxidant combinations can better optimize the oxygen free radicals in energy and substance metabolism, resist the degeneration and aging of the body, keep the body healthy and prolong life.
- blood homocysteine is an intermediate product of methionine metabolism, and its synthetic metabolic pathway and related enzyme system ( Methionine synthase, cystathionine ⁇ synthase) deficiency, folic acid, B12, B6 deficiency can cause hyperhomocysteinemia.
- the average prevalence of high blood homocysteine in China is 27.5%.
- the special cooking methods of the Chinese population such as frying and stir-frying, destroy folic acid during this cooking process, resulting in the lack of folic acid and other vitamins in most people.
- Long-term deficiency It affects energy metabolism, protein metabolism and the formation of nucleic acid, leading to hyperhomocysteinemia and the occurrence of various diseases.
- Our drink is the function of various nutrients to maintain the human body during energy metabolism.
- various vitamins play the role of coenzyme, it strengthens the metabolic pathway of methionine, reduces blood homocysteine, and makes methionine metabolism go smoothly. Perfectly promote energy metabolism and protein nucleic acid metabolism, avoid various diseases, including arteriosclerotic cardiovascular and cerebrovascular diseases.
- Methionine cycle and transmethylation Methionine (methionine) containing S-methyl must be combined with ATP before transmethylation to generate S-adenosylmethionine (SAM, also known as is active methionine), under the action of methyltransferase, SAM can transfer the methyl group to the methyl group acceptor, make it methylated, and generate methylated products (such as: choline), while At the same time, SAM is converted into S-adenosyl-homocysteine after demethylation, and then further adenosine is removed to generate homocysteine.
- SAM also known as is active methionine
- Homocysteine can accept the methyl group provided by N5-methyltetrahydrofolate to regenerate methionine (methionine), thus forming a cyclic process called methionine (methionine) cycle.
- the enzyme that catalyzes the transmethylation of N5-methyltetrahydrofolate to generate methionine is called methionine synthase (also known as: methionine methyltransferase, N5-methyltetrahydrofolate transmethylase), and its coenzyme is VB12 (vitamin B12), which is involved in the transfer of methyl groups.
- choline can further generate lecithin (promote myelin production) or form acetylcholine (involved in the recovery of neurotransmitters).
- N5-methyltetrahydrofolate is demethylated by methionine transferase to form tetrahydrofolate, which accepts the one-carbon unit provided by amino acids , form N10-formyltetrahydrofolate and then further generate N5, N10-methyltetrahydrofolate, which forms N5-methyltetrahydrofolate through the action of N5, N10-methylenetetrahydrofolate reductase, forming another A cycle ⁇ "one carbon unit cycle".
- N5 N10-methylenetetrahydrofolate reductase is the key coenzyme of thymidylate synthase, which can catalyze the conversion of deoxyguanosine monophosphate (d-UMP) into monophosphate in the necessary reaction of pyrimidine biosynthesis.
- d-UMP deoxyguanosine monophosphate
- d-TMP Deoxythymidine phosphate
- Cystinemia is an independent risk factor for diseases such as atherosclerosis, stroke, and dementia.
- the embodiment of the present invention provides an antioxidant nutritional combination capsule, which combines various antioxidants such as ⁇ -nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid, etc., and synergistically enhances anti-oxidation and anti-aging
- the effect is to protect the tissue cells of the whole body, so that the tissue cells of the whole body can maintain a healthy and young state and make life longer; at the same time, it is designed for the defects of the Chinese diet characteristics, preventing energy and material metabolism disorders caused by the lack of certain nutrients.
- the combination of vitamin B6, vitamin B12 and folic acid can promote the metabolism of methionine and realize the hub of human energy metabolism and material metabolism. It can effectively prevent arteriosclerosis and make various metabolisms of the human body go on healthily. Oxidation, anti-aging and other effects can protect the heart and vital organs of the body, and can maintain the health of human body functions.
- the anti-oxidation nutrition combination capsule of the embodiment of the present invention expands the types of anti-oxidation preparations of existing products and strengthens the anti-oxidation effect. It combines multiple antioxidants such as ⁇ -nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid, etc., synergistically enhances the anti-oxidation and anti-aging effects, protects the tissue cells of the whole body, and is the maintenance of the tissue cells of the whole body. A healthy and youthful state makes life longer.
- the anti-oxidant nutritional combination capsule of the embodiment of the present invention is designed for the defects of the Chinese diet characteristics, to prevent energy and substance metabolism disorders caused by the lack of certain nutrients, combined with vitamin B6, vitamin B12 and folic acid, It promotes the metabolism of methionine, effectively prevents arteriosclerosis, and makes various metabolisms of the human body go on healthily.
- the anti-oxidation nutritional combination capsule of the embodiment of the present invention adds multiple vitamins to promote more comprehensive energy metabolism and substance metabolism of the body.
- the anti-oxidation nutritional combination capsule of the embodiment of the present invention promotes the methionine metabolism pathway, better coordinates protein metabolism, nucleic acid metabolism and energy metabolism, prevents various metabolic diseases, and alleviates arteriosclerosis throughout the human body.
- the anti-oxidation nutritional combination capsule of the embodiment of the present invention is added with various anti-oxidation preparations, synergistically, mutually reinforcing, has the functions of anti-oxidation, anti-aging, and protecting tissue cells, and at the same time has the functions of regulating metabolism and anti-tumor, making the body healthier, live longer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antioxidant capsule, comprising a plurality of antioxidants such as β-nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C and lipoic acid.
Description
本发明涉及保健产品技术领域,尤其涉及一种抗氧化营养组合胶囊。The invention relates to the technical field of health care products, in particular to an antioxidant nutritional combination capsule.
人们在正常生活中,生命的维持需要体内复杂的生化反应,产生能量代谢及物质代谢,来维持人体各器官功能的正常运行,其中有多种物质在复杂的机体生化反应中起了重要的作用,如果没有这些物质,机体就不能生存,这些物质被认为是人体重要的营养物质,包括多种维生素和其他生化物质等。In people's normal life, the maintenance of life requires complex biochemical reactions in the body to produce energy metabolism and material metabolism to maintain the normal operation of the functions of various organs in the human body. Many substances play an important role in the complex biochemical reactions of the body , Without these substances, the body cannot survive. These substances are considered to be important nutrients for the human body, including multivitamins and other biochemical substances.
在人体内的能量及物质代谢当中,三羧酸循环是能量代谢的枢纽,在全身细胞的线粒体当中进行,通过三羧酸循环,产生较多的能量,维持人体的各种生理、生化的正常进行,以维持人体的正常机能运行。但在产生能量的过程中,同时会产生多种氧化物质,这种氧化物质多数为代谢中产生的电子,在组织中形成氧化自由基,造成组织细胞的氧化损伤,造成人体细胞组织的变性及老化。这就需要抗氧化剂来对抗这种氧化自由基,随时来保护人体在能量代谢中产生的氧化自由基所带来的全身组织损伤,使机体免于氧化损伤所带来的过早老化及衰老,从而延长人体的寿命。In the energy and substance metabolism in the human body, the tricarboxylic acid cycle is the hub of energy metabolism. It is carried out in the mitochondria of the cells of the whole body. Through the tricarboxylic acid cycle, more energy is generated to maintain the normal physiological and biochemical conditions of the human body. To maintain the normal functioning of the human body. However, in the process of energy generation, a variety of oxidative substances will be produced at the same time. Most of these oxidative substances are electrons generated in metabolism, which form oxidative free radicals in tissues, causing oxidative damage to tissue cells, resulting in denaturation and death of human cell tissues. Ageing. This requires antioxidants to fight against this kind of oxidative free radicals, to protect the body's tissue damage caused by oxidative free radicals produced in energy metabolism at any time, and to prevent the body from premature aging and aging caused by oxidative damage. Thereby prolonging the life of the human body.
现有市面上的抗氧化自由基中,大部分都是单独的抗氧化成分,这些成分在对抗氧化自由基当中虽然起了一定的作用,有利于维护机体的健康状态;但是因为市面上这种抗氧化剂其所含的成分较为单一,抗氧化作用有限,不能更好满足全身细胞组织抗氧化的需要,不能弥补全身各组织细胞所产生的氧化自由基所带来的损害,故不能更好的消除人体能量代谢中所产生的健康隐患。Most of the existing antioxidant free radicals on the market are independent antioxidant ingredients. Although these ingredients play a certain role in the antioxidant free radicals, they are beneficial to maintaining the health of the body; Antioxidants contain a relatively single component, and their antioxidant effects are limited. They cannot better meet the antioxidant needs of the whole body's cells and tissues, and cannot compensate for the damage caused by oxidative free radicals produced by various tissue cells throughout the body, so they cannot be better. Eliminate the health hazards generated in the energy metabolism of the human body.
随着人们生活及健康需求的不断提高,设计一种营养物质更全面,兼顾更完善的抗氧化剂组合,同时又能在能量和物质代谢中补充损害的营养物质,延缓衰老,保护机体组织保持年轻状态,是目前市面上抗氧化制剂的必然需 求。随着人们健康延寿意识的不断提高,这种抗氧化组合制剂的需求量也会不断增加。With the continuous improvement of people's life and health needs, it is necessary to design a combination of nutrients that are more comprehensive and comprehensive, and at the same time supplement damaged nutrients in energy and substance metabolism, delay aging, and protect body tissues to keep young It is an inevitable demand for antioxidant preparations currently on the market. With the continuous improvement of people's awareness of health and life extension, the demand for this antioxidant combination preparation will also continue to increase.
发明内容Contents of the invention
本发明提供一种抗氧化营养组合胶囊,含有较多人体能量代谢中需要的营养物质,保证人体正常的能量及物质代谢,同时具有较明显的抗氧化,抗衰老,维持人体机能的健康状态,延长寿命。The invention provides an anti-oxidation nutrition combination capsule, which contains more nutrients needed in the energy metabolism of the human body, ensures the normal energy and substance metabolism of the human body, and has obvious anti-oxidation, anti-aging, and maintains the healthy state of human body functions. extend your life.
本发明提供的具体技术方案如下:The concrete technical scheme that the present invention provides is as follows:
一方面,本发明提供的一种抗氧化营养组合胶囊中含有150~900mg的β-烟酰胺单核苷酸、10~50mg的辅酶Q10、50~500mg的维生素E、100~1000mg的维生素C、50~300mg的硫辛酸、0.4~5mg维生素B6、10~100ug的维生素B12和20~200ug叶酸;所述抗氧化营养组合胶囊平均粒重为0.5g,所述抗氧化营养组合胶囊的内容物平均体积为0.68mL。On the one hand, an antioxidant nutritional combination capsule provided by the present invention contains 150-900 mg of β-nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300mg of lipoic acid, 0.4-5mg of vitamin B6, 10-100ug of vitamin B12 and 20-200ug of folic acid; the average grain weight of the antioxidant nutrition combination capsule is 0.5g, and the content of the antioxidant nutrition combination capsule is on average The volume is 0.68 mL.
可选的,所述维生素B6、所述维生素B12、所述叶酸相互配合以促进蛋氨酸循环。Optionally, the vitamin B6, the vitamin B12, and the folic acid cooperate with each other to promote the circulation of methionine.
可选的,所述维生素E是一种脂溶性维生素,所述维生素E的水解产物为生育酚,所述维生素C是一种多羟基化合物,所述维生素B6包括吡哆醇、吡哆醛和吡哆胺。Optionally, the vitamin E is a fat-soluble vitamin, the hydrolyzate of the vitamin E is tocopherol, the vitamin C is a polyhydroxy compound, and the vitamin B6 includes pyridoxine, pyridoxal and Pyridoxamine.
可选的,每粒所述抗氧化营养组合胶囊中还含有明胶、甘油、水和焦糖色素。Optionally, each capsule of the antioxidant nutrition combination also contains gelatin, glycerin, water and caramel coloring.
可选的,每粒所述抗氧化营养组合胶囊中含有200mg的β-烟酰胺单核苷酸、40mg的辅酶Q10、50mg的维生素E、100mg的维生素C、50mg的硫辛酸、5mg维生素B6、100ug的维生素B12和200ug叶酸。Optionally, each capsule of the antioxidant nutrition combination contains 200mg of β-nicotinamide mononucleotide, 40mg of coenzyme Q10, 50mg of vitamin E, 100mg of vitamin C, 50mg of lipoic acid, 5mg of vitamin B6, 100ug of vitamin B12 and 200ug of folic acid.
可选的,所述β-烟酰胺单核苷酸、所述辅酶Q10、所述维生素E、所述维生素C和所述硫辛酸相互配合且协同作用形成抗氧化组合。Optionally, the β-nicotinamide mononucleotide, the coenzyme Q10, the vitamin E, the vitamin C and the lipoic acid cooperate with each other and act synergistically to form an antioxidant combination.
可选的,所述维生素E、所述维生素C和所述硫辛酸协同所述辅酶Q10实现联合抗氧化作用。Optionally, the vitamin E, the vitamin C and the lipoic acid cooperate with the coenzyme Q10 to achieve a combined antioxidant effect.
本发明的有益效果如下:The beneficial effects of the present invention are as follows:
本发明实施例提供一种抗氧化营养组合胶囊,组合了β烟酰胺单核苷酸、辅酶Q10、维生素E、维生素C、硫辛酸等多种抗氧化剂,协同作用,互相增强抗氧化及抗衰老效果,保护全身组织细胞,是全身组织细胞保持健康年轻态,使生命更长久;同时针对于中国饮食特点的缺陷设计而成,防止因某些营养物质的缺乏导致的能量及物质代谢障碍,组合了维生素B6、维生素B12及叶酸组合,三者相互配合可以促进蛋氨酸代谢,实现人体能量代谢及物质代谢的枢纽,具有有效预防动脉硬化,使人体各种代谢健康地进行,增加了辅酶Q10具有抗氧化、抗衰老等功效,可以起到保护心脏及身体重要器官的作用,可以维持人体机能的健康状态。The embodiment of the present invention provides an antioxidant nutritional combination capsule, which combines various antioxidants such as β-nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid, etc., and synergistically enhances anti-oxidation and anti-aging The effect is to protect the tissue cells of the whole body, so that the tissue cells of the whole body can maintain a healthy and young state and make life longer; at the same time, it is designed for the defects of the Chinese diet characteristics, preventing energy and material metabolism disorders caused by the lack of certain nutrients. The combination of vitamin B6, vitamin B12 and folic acid can promote the metabolism of methionine and realize the hub of human energy metabolism and material metabolism. It can effectively prevent arteriosclerosis and make various metabolisms of the human body go on healthily. Oxidation, anti-aging and other effects can protect the heart and vital organs of the body, and can maintain the health of human body functions.
为了使本发明的目的、技术方案和优点更加清楚,下面对本发明作进一步地详细描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。In order to make the purpose, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below. Obviously, the described embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
本发明实施例提供的一种抗氧化营养组合胶囊中含有150~900mg的β-烟酰胺单核苷酸、10~50mg的辅酶Q10、50~500mg的维生素E、100~1000mg的维生素C、50~300mg的硫辛酸、0.4~5mg维生素B6、10~100ug的维生素B12和20~200ug叶酸;抗氧化营养组合胶囊平均粒重为0.5g,抗氧化营养组合胶囊的内容物平均体积为0.68mL。其中,维生素B6、维生素B12、叶酸相互配合以促进蛋氨酸循环。维生素E是一种脂溶性维生素,维生素E的水解产物为生育酚,维生素C是一种多羟基化合物,维生素B6包括吡哆醇、吡哆醛和吡哆胺。An antioxidant nutritional combination capsule provided in the embodiment of the present invention contains 150-900 mg of β-nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50 ~300mg of lipoic acid, 0.4~5mg of vitamin B6, 10~100ug of vitamin B12 and 20~200ug of folic acid; the average grain weight of the antioxidant nutrition combination capsule is 0.5g, and the average volume of the content of the antioxidant nutrition combination capsule is 0.68mL. Among them, vitamin B6, vitamin B12, and folic acid cooperate with each other to promote the circulation of methionine. Vitamin E is a fat-soluble vitamin, the hydrolysis product of vitamin E is tocopherol, vitamin C is a polyhydroxy compound, and vitamin B6 includes pyridoxine, pyridoxal and pyridoxamine.
进一步的,每粒本发明实施例提供的一种抗氧化营养组合胶囊中还含有明胶、甘油、水和焦糖色素。优选的,每粒抗氧化营养组合胶囊中含有200mg的β-烟酰胺单核苷酸、40mg的辅酶Q10、50mg的维生素E、100mg的维生 素C、50mg的硫辛酸、5mg维生素B6、100ug的维生素B12和200ug叶酸,该配比下的抗氧化营养组合胶囊的抗氧化效果最好。Further, each capsule of an antioxidant nutritional combination provided by the embodiment of the present invention also contains gelatin, glycerin, water and caramel coloring. Preferably, each antioxidant nutrition combination capsule contains 200mg of β-nicotinamide mononucleotide, 40mg of coenzyme Q10, 50mg of vitamin E, 100mg of vitamin C, 50mg of lipoic acid, 5mg of vitamin B6, and 100ug of vitamin B12 and 200ug folic acid, the anti-oxidation nutritional combination capsule with this ratio has the best anti-oxidation effect.
本发明实施例提供的一种抗氧化营养组合胶囊中β-烟酰胺单核苷酸、辅酶Q10、维生素E、维生素C和硫辛酸相互配合且协同作用形成抗氧化组合。维生素E、维生素C和硫辛酸协同辅酶Q10实现联合抗氧化作用。In the antioxidant nutritional combination capsule provided by the embodiment of the present invention, β-nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C and lipoic acid cooperate with each other and act synergistically to form an antioxidant combination. Vitamin E, vitamin C and lipoic acid synergize with coenzyme Q10 to achieve a joint antioxidant effect.
本发明实施例提供的一种抗氧化营养组合胶囊中采用的β烟酰胺单核苷酸(Nicotinamide mononucleotide,NMN),在人体细胞能量生成中扮演重要角色,它参与细胞内NAD+(又称烟酰胺腺嘌呤二核苷酸,细胞能量转化的重要辅酶)的合成,是NAD+的前体物质。经过大量的研究发现,人为补充NMN,可大幅提升NAD+水平,对心脑血管疾病、神经退行性病及老化退行性疾病等有较好的治疗和修复作用,这也是NMN逆转衰老、延长寿命的核心机制;另外,NMN还可通过参与和调节机体的内分泌起到保护和修复胰岛功能,增加胰岛素的分泌,防治糖尿病和肥胖等代谢性疾病的作用;同时,还可以预防和治疗肥胖,保护心脏免于缺血再灌注损伤,对视网膜退行性疾病、2型糖尿病、脑出血等均具有一定预防及治疗作用。定期摄入NMN可以有效地增加NAD+在体内的含量,从而帮助人类自身修复DNA的损伤、预防退化性疾病,延缓衰老。The β-nicotinamide mononucleotide (Nicotinamide mononucleotide, NMN) used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention plays an important role in the energy generation of human cells, and it participates in the intracellular NAD+ (also known as nicotinamide Adenine dinucleotide, an important coenzyme for cellular energy conversion), is the precursor of NAD+. After a lot of research, it has been found that artificial supplementation of NMN can greatly increase the level of NAD+, and has a good therapeutic and repair effect on cardiovascular and cerebrovascular diseases, neurodegenerative diseases, and aging degenerative diseases. This is also the core of NMN to reverse aging and prolong life. In addition, NMN can also protect and repair islet function, increase insulin secretion, and prevent and treat metabolic diseases such as diabetes and obesity by participating in and regulating the endocrine of the body; at the same time, it can also prevent and treat obesity, protect the heart immune In ischemia-reperfusion injury, it has a certain preventive and therapeutic effect on retinal degenerative diseases, type 2 diabetes, and cerebral hemorrhage. Regular intake of NMN can effectively increase the content of NAD+ in the body, thereby helping humans repair DNA damage, prevent degenerative diseases, and delay aging.
本发明实施例提供的一种抗氧化营养组合胶囊中采用的辅酶Q10不仅能给心脏提供动力,还具有卓越的抗氧化、清除自由基功能,能预防血管壁脂质过氧化,预防动脉粥样硬化,并且无任何毒副作用。其采用的维生素E(Vitamin E)是一种脂溶性维生素,其水解产物为生育酚,生育酚是最主要的抗氧化剂之一。维生素E能促进生殖功能、保护T淋巴细胞、保护红细胞、抗自由基氧化、抑制血小板聚集从而降低心肌梗死和脑梗塞的危险性;还对烧伤、冻伤、毛细血管出血、更年期综合症、美容等方面有很好的疗效;可抑制眼睛晶状体内的过氧化脂反应,使末梢血管扩张,改善血液循环;可有效对抗自由基,抑制过氧化脂质生成,祛除黄褐斑;抑制酪氨酸酶的活性, 从而减少黑色素生成;酯化形式的维生素E还能消除由紫外线、空气污染等外界因素造成的过多的氧自由基,起到延缓光老化、预防晒伤和抑制日晒红斑生成等作用。The coenzyme Q10 used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention can not only provide power to the heart, but also has excellent anti-oxidation and free radical scavenging functions, can prevent lipid peroxidation in blood vessel walls, and prevent atherosclerosis Hardened, and without any side effects. The vitamin E (Vitamin E) it uses is a fat-soluble vitamin, and its hydrolyzed product is tocopherol, which is one of the most important antioxidants. Vitamin E can promote reproductive function, protect T lymphocytes, protect red blood cells, resist free radical oxidation, inhibit platelet aggregation, thereby reducing the risk of myocardial infarction and cerebral infarction; It has a good curative effect; it can inhibit the lipid peroxide reaction in the lens of the eye, expand the peripheral blood vessels, and improve blood circulation; it can effectively fight against free radicals, inhibit the generation of lipid peroxide, and remove chloasma; inhibit tyrosinase The activity of melanin, thereby reducing the production of melanin; the esterified form of vitamin E can also eliminate the excessive oxygen free radicals caused by external factors such as ultraviolet rays and air pollution, so as to delay photoaging, prevent sunburn and inhibit the formation of sun erythema, etc. effect.
本发明实施例提供的一种抗氧化营养组合胶囊中采用的维生素C的结构类似葡萄糖,是一种多羟基化合物。维生素C具有很强的还原性,很容易被氧化成脱氢维生素C,但其反应是可逆的,并且抗坏血酸和脱氢抗坏血酸具有同样的生理功能。维生素C为抗体及胶原形成,组织修补(包括某些氧化还原作用),苯丙氨酸、酪氨酸、叶酸的代谢,铁、碳水化合物的利用,脂肪、蛋白质的合成,维持免疫功能,羟化5-羟色胺,保持血管的完整,促进非血红素铁吸收等所必需,同时维生素C还具备有抗氧化,抗自由基,抑制酪氨酸酶的形成,从而达到美白,淡斑的功效。维生素C的抗氧化作用可以理解为是一种“保护作用”,在现代医疗上也可以利用维生素C较强的抗氧化作用,抑制自由基对人体氧化的损害,从而预防肿瘤和癌症的侵袭。The structure of the vitamin C used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention is similar to that of glucose, and is a polyhydroxy compound. Vitamin C has a strong reducing property and is easily oxidized to dehydrovitamin C, but the reaction is reversible, and ascorbic acid and dehydroascorbic acid have the same physiological function. Vitamin C is for the formation of antibodies and collagen, tissue repair (including certain redox effects), metabolism of phenylalanine, tyrosine, and folic acid, utilization of iron and carbohydrates, synthesis of fat and protein, maintenance of immune function, hydroxyl Antioxidant 5-hydroxytryptamine is necessary to maintain the integrity of blood vessels and promote the absorption of non-heme iron. At the same time, vitamin C also has anti-oxidation, anti-free radicals, and inhibits the formation of tyrosinase, so as to achieve the effect of whitening and lightening spots. The antioxidant effect of vitamin C can be understood as a "protective effect". In modern medicine, the strong antioxidant effect of vitamin C can also be used to inhibit free radicals from oxidative damage to the human body, thereby preventing the invasion of tumors and cancers.
本发明实施例提供的一种抗氧化营养组合胶囊中采用的硫辛酸是一种存在于线粒体的辅酶,类似维他命,能消除导致加速老化与致病的自由基。硫辛酸在体内经肠道吸收后进入细胞,兼具脂溶性与水溶性的特性。作为辅酶,在两个关键性的氧化脱羧反应中起作用,即在丙酮酸脱氢酶复合体和α-酮戊二酸脱氢酶复合体中,催化酰基的产生和转移。α-硫辛酸含有双硫五元环结构,电子密度很高,具有显著的亲电子性和与自由基反应的能力,因此它具有抗氧化性,具有极高的保健功能和医用价值(如抗脂肪肝和降低血浆胆固醇的作用)。此外,硫辛酸的巯基很容易进行氧化还原反应,故可保护巯基酶免受重金属离子的毒害。硫辛酸进入人体后易还原为双氢硫辛酸,两者均能促使维生素C、维生素E的再生,发挥抗氧化作用。本药还可增加细胞内谷胱甘肽及辅酶Q10并可螯合某些金属离子。The lipoic acid used in the antioxidant nutritional combination capsule provided by the embodiment of the present invention is a coenzyme existing in mitochondria, similar to vitamins, and can eliminate free radicals that lead to accelerated aging and disease. Alpha lipoic acid enters the cells after being absorbed by the intestines in the body, and has both fat-soluble and water-soluble properties. As a coenzyme, it plays a role in two key oxidative decarboxylation reactions, that is, in the pyruvate dehydrogenase complex and the α-ketoglutarate dehydrogenase complex, catalyzing the generation and transfer of acyl groups. α-lipoic acid contains a disulfide five-membered ring structure, has a high electron density, has significant electrophilicity and the ability to react with free radicals, so it has antioxidant properties, and has extremely high health care functions and medical value (such as anti fatty liver and lowering of plasma cholesterol). In addition, the sulfhydryl group of lipoic acid is easy to undergo redox reaction, so it can protect the sulfhydryl enzyme from the poison of heavy metal ions. After lipoic acid enters the human body, it is easily reduced to dihydrolipoic acid, both of which can promote the regeneration of vitamin C and vitamin E, and play an antioxidant role. The drug can also increase intracellular glutathione and coenzyme Q10 and can chelate certain metal ions.
本发明实施例提供的一种抗氧化营养组合胶囊中采用的维生素B6包括吡哆醇、吡哆醛及吡哆胺,是一种水溶性维生素,遇光或碱易破坏,不耐高 温。参与蛋白质合成与分解代谢,参与所有氨基酸代谢;参与蛋白质合成与分解代谢,参与所有氨基酸代谢尤其是蛋氨酸的代谢;维持身体机能的重要物质。其采用的维生素B12可以参与蛋氨酸、胸腺嘧啶等的合成,促进红细胞的发育和成熟,具有活化氨基酸的作用和促进核酸的生物合成,可促进蛋白质的合成代谢,使脂肪酸、碳水化合物、蛋白质被身体适当运用;是神经系统功能健全不可缺少的维生素,参与神经组织中一种脂蛋白的形成,维护神经髓鞘的代谢与功能。The vitamin B6 used in the anti-oxidation nutritional combination capsule provided by the embodiment of the present invention includes pyridoxine, pyridoxal and pyridoxamine, and is a water-soluble vitamin that is easily destroyed by light or alkali and is not resistant to high temperature. Participate in protein synthesis and catabolism, participate in all amino acid metabolism; participate in protein synthesis and catabolism, participate in all amino acid metabolism, especially the metabolism of methionine; an important substance to maintain body functions. The vitamin B12 used in it can participate in the synthesis of methionine, thymine, etc., promote the development and maturation of red blood cells, have the function of activating amino acids and promote the biosynthesis of nucleic acids, and can promote the synthesis and metabolism of proteins, so that fatty acids, carbohydrates, and proteins are absorbed by the body. Appropriate use; it is an indispensable vitamin for the healthy function of the nervous system, participates in the formation of a lipoprotein in the nerve tissue, and maintains the metabolism and function of the nerve myelin sheath.
β-烟酰胺单核苷酸、辅酶Q10、维生素E、维生素C和硫辛酸相互配合且协同作用形成抗氧化组合,具有特殊的保健作用。其中,β-烟酰胺单核苷酸(Nicotinamide mononucleotide,NMN),在人体细胞能量生成中扮演重要角色,它参与细胞内NAD+(烟酰胺腺嘌呤二核苷酸,细胞能量转化的重要辅酶)的合成。NAD+又叫辅酶Ⅰ,全称烟酰胺腺嘌呤二核苷酸,又称二磷酸烟苷,存在每一个细胞中参与上千项反应,参与了人体新陈代谢的方方面面,是关键性的辅酶。但是随着年龄的增长,人体内的NAD+水平是在逐渐下降的,40岁时,人体内NAD+水平仅为孩童时期的25%,80岁以后则下降至婴儿时期的6.25%,NAD+的下降,会导致线粒体活性降低,加速线粒体、细胞乃至整个机体的衰老,并且逐渐进入恶性循环,这就是我们变老和发生疾病的原因。NAD+分子量较大,不能直接通过口服产生,但由于β-烟酰胺单核苷酸(NMN)是NAD+的前体物质,可通过口服补充NMN来增加NAD+的含量,进而绕过了NAMPT限速酶的瓶颈,可以迅速补充体内NAD+,是最佳及最科学的补充方法。β-nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C and lipoic acid cooperate with each other and synergistically form an antioxidant combination, which has a special health care effect. Among them, β-nicotinamide mononucleotide (Nicotinamide mononucleotide, NMN) plays an important role in the energy generation of human cells. synthesis. NAD+, also known as coenzyme Ⅰ, the full name of nicotinamide adenine dinucleotide, also known as nicotinic acid diphosphate, exists in every cell and participates in thousands of reactions, participating in all aspects of human metabolism, and is a key coenzyme. However, as the age increases, the NAD+ level in the human body is gradually declining. At the age of 40, the NAD+ level in the human body is only 25% of the childhood level, and after the age of 80, it drops to 6.25% of the infant level. The decline of NAD+, It will lead to the reduction of mitochondrial activity, accelerate the aging of mitochondria, cells and even the whole body, and gradually enter a vicious circle. This is the reason why we get old and develop diseases. NAD+ has a large molecular weight and cannot be produced directly by oral administration, but since β-nicotinamide mononucleotide (NMN) is the precursor of NAD+, NAD+ content can be increased by oral supplementation of NMN, thereby bypassing the NAMPT rate-limiting enzyme It is the best and most scientific way to replenish NAD+ in the body quickly.
NMN是哺乳动物体内烟酰胺腺嘌呤二核苷酸(Nicotinamide adenine dinucleotide,NAD+)补救合成途径的中间体。NMN(烟酰胺单核苷酸)是烟酰胺磷酸核糖转移酶(Nicotinamide phosphate ribose transferase,Nampt)反应的产物,是NAD+的关键前体之一。在哺乳动物体内,NMN由烟酰胺(Nicotinamide,Nam)在Nampt的催化下生成,随后NMN在烟酰胺单核苷酸腺苷转移酶 (Nicotinamide mononucleotideadenosine transferase,Nmnat)的催化下生成NAD+。细胞外NMN需要去磷酸转化为烟酰胺核苷(Nicotinamide riboside,NR)才能进入肝细胞内部,进入胞内后,NR在烟酰胺核苷激酶1(Nicotinamide riboside kinase,NRK1)的作用下磷酸化生成NMN,随后NMN和ATP结合生成NAD+。NMN在人体内通过转化为NAD+来发挥其生理功能,如激活NAD+底物依赖性酶Sirt1(组蛋白脱乙酰酶,又称沉默调节蛋白)、调节细胞存活和死亡、维持氧化还原状态等。定期摄入NMN,可以有效地增加NAD+在体内的含量,从而帮助人类自身修复DNA的损伤、预防退化性疾病,延缓衰老。这也是NMN逆转衰老,延长寿命的核心机制。NMN is an intermediate in the salvage synthesis pathway of nicotinamide adenine dinucleotide (NAD+) in mammals. NMN (nicotinamide mononucleotide) is the product of nicotinamide phosphate ribose transferase (Nampt) reaction and is one of the key precursors of NAD+. In mammals, NMN is generated from Nicotinamide (Nam) under the catalysis of Nampt, and then NMN is catalyzed by Nicotinamide mononucleotide adenosine transferase (Nmnat) to generate NAD+. Extracellular NMN needs to be dephosphorylated and transformed into nicotinamide riboside (NR) to enter the interior of liver cells. After entering the cell, NR is phosphorylated by nicotinamide riboside kinase 1 (Nicotinamide riboside kinase, NRK1) to generate NMN, followed by the combination of NMN and ATP to generate NAD+. NMN exerts its physiological functions by converting into NAD+ in the human body, such as activating NAD+ substrate-dependent enzyme Sirt1 (histone deacetylase, also known as sirtuin), regulating cell survival and death, maintaining redox state, etc. Regular intake of NMN can effectively increase the content of NAD+ in the body, thereby helping humans repair DNA damage, prevent degenerative diseases, and delay aging. This is also the core mechanism for NMN to reverse aging and prolong life.
三羧酸循环(tricarboxylic acid cycle,TCA cycle)是需氧生物体内普遍存在的代谢途径。原核生物中分布于细胞质,真核生物中分布在线粒体。因为在这个循环中几个主要的中间代谢物是含有三个羧基的有机酸,例如柠檬酸,所以叫做三羧酸循环,又称为柠檬酸循环或者是TCA循环。三羧酸循环是三大营养素(糖类、脂类、氨基酸)的最终代谢通路,又是糖类、脂类、氨基酸代谢联系的枢纽。The tricarboxylic acid cycle (TCA cycle) is a metabolic pathway ubiquitous in aerobic organisms. It is distributed in the cytoplasm in prokaryotes and in the mitochondria in eukaryotes. Because several main intermediate metabolites in this cycle are organic acids containing three carboxyl groups, such as citric acid, it is called tricarboxylic acid cycle, also known as citric acid cycle or TCA cycle. The tricarboxylic acid cycle is the final metabolic pathway of the three major nutrients (sugars, lipids, and amino acids), and it is also the hub of the metabolic connection of sugars, lipids, and amino acids.
在三羧酸循环的过程中,随着代谢的进行,会产生大量的电子,电子是一种氧化剂,即氧自由基,自由基是细胞正常的代谢产物,一般情况下,自由基的产生和清除处于一个动态平衡状态,一旦平衡被打破,体内自由基的积聚可引起氧化应激,导致DNA、脂质和蛋白质的过氧化,引起线粒体功能障碍和细胞凋亡。氧化应激和线粒体功能障碍互为因果,形成恶性循环,使人体代谢组织发生变性,衰老。In the process of the tricarboxylic acid cycle, with the progress of metabolism, a large number of electrons will be produced. Electrons are a kind of oxidant, that is, oxygen free radicals. Free radicals are normal metabolic products of cells. Generally, the production of free radicals and Clearance is in a state of dynamic balance. Once the balance is broken, the accumulation of free radicals in the body can cause oxidative stress, leading to the peroxidation of DNA, lipids and proteins, causing mitochondrial dysfunction and apoptosis. Oxidative stress and mitochondrial dysfunction are mutually causal, forming a vicious circle, which leads to the degeneration and aging of human metabolic tissues.
辅酶Q10是人体内唯一天然存在的、可再生的脂溶性抗氧化剂。机体中辅酶Q10有2种存在形式,包括氧化型和还原型,2种形式在体内可以相互转换,但只有还原型辅酶Q10才能在机体内发挥抗氧化作用。辅酶Q10的抗氧化性主要体现在清除自由基、与其它抗氧化物质的协同作用、抗细胞凋亡 和稳定细胞膜。辅酶Q10可通过氧化还原型结构的转换,清除体内的自由基,减少氧化应激,同时改善线粒体功能障碍。Coenzyme Q10 is the only naturally occurring, renewable, fat-soluble antioxidant in the human body. There are two forms of coenzyme Q10 in the body, including the oxidized form and the reduced form. The two forms can be converted into each other in the body, but only the reduced form of coenzyme Q10 can play an antioxidant role in the body. The antioxidant activity of coenzyme Q10 is mainly reflected in scavenging free radicals, synergistic effect with other antioxidant substances, anti-apoptosis and stabilizing cell membrane. Coenzyme Q10 can scavenge free radicals in the body, reduce oxidative stress, and improve mitochondrial dysfunction through the conversion of redox structure.
辅酶Q10抑制细胞凋亡的作用机理可能包含:①保护线粒体DNA,辅酶Q10可以清除氧自由基,减少氧化应激,阻止过氧化损伤引起的线粒体DNA突变,维持线粒体呼吸链的完整性,减少细胞凋亡;②辅酶Q10可以增加线粒体ATP的产生效率,促进细胞新陈代谢和生长,减缓细胞的凋亡;③抑制线粒体去极化:辅酶Q10可以通过抑制线粒体渗透性转换通道的开放,阻止线粒体的去极化,从而抑制细胞色素C的释放及前半胱天冬酶-9(procaspase-9)的激活,抑制线粒体依赖的凋亡通路活化,发挥抗细胞凋亡作用;④抑制活性氧(ROS)相关的凋亡通路:在肾近曲小管细胞中,辅酶Q10显著抑制尼古丁诱导的ROS生成及细胞凋亡,其机制为辅酶Q10磷酸化p66shc,继而激活抗氧化反应元件(antioxidant responseelement,ARE)及锰超氧化物歧化酶(manganese superoxide dismutase,MnSOD)的启动子,促使MnSOD清除ROS,从而抑制细胞凋亡。通过辅酶Q10的抗氧化作用,增强心脏功能的同时,防止衰老及老化,使机体保持年轻态。The mechanism of action of Coenzyme Q10 in inhibiting apoptosis may include: ① Protecting mitochondrial DNA, Coenzyme Q10 can scavenge oxygen free radicals, reduce oxidative stress, prevent mitochondrial DNA mutation caused by peroxidative damage, maintain the integrity of mitochondrial respiratory chain, reduce cell Apoptosis; ②Coenzyme Q10 can increase the production efficiency of mitochondrial ATP, promote cell metabolism and growth, and slow down cell apoptosis; ③Inhibit mitochondrial depolarization: Coenzyme Q10 can prevent mitochondrial depolarization by inhibiting the opening of mitochondrial permeability transition channels Polarization, thereby inhibiting the release of cytochrome C and the activation of procaspase-9 (procaspase-9), inhibiting the activation of mitochondria-dependent apoptotic pathways, and exerting an anti-apoptotic effect; ④ inhibiting reactive oxygen species (ROS) related Apoptotic pathway: In renal proximal tubule cells, coenzyme Q10 significantly inhibited nicotine-induced ROS production and cell apoptosis, the mechanism is that coenzyme Q10 phosphorylates p66shc, and then activates antioxidant response element (antioxidant response element, ARE) and manganese The promoter of superoxide dismutase (manganese superoxide dismutase, MnSOD) promotes MnSOD to remove ROS, thereby inhibiting cell apoptosis. Through the antioxidant effect of coenzyme Q10, while enhancing heart function, it prevents aging and aging, and keeps the body young.
本发明实施例的抗氧化营养组合胶囊中的维生素E、维生素C和硫辛酸协同辅酶Q10实现联合抗氧化作用。其中,尤其硫辛酸进入人体后易还原为双氢硫辛酸,硫辛酸和辅酶Q10相互配合均能促使维生素C、维生素E的再生,发挥抗氧化作用。本发明实施例的抗氧化营养组合胶囊还可增加细胞内谷胱甘肽及辅酶Q10并可螯合某些金属离子。数种抗氧化组合能更好的优化能量及物质代谢中的氧自由基,抵抗机体的变性及老化,使机体保持健康状态,延长寿命。The vitamin E, vitamin C and lipoic acid in the antioxidant nutritional combination capsule of the embodiment of the present invention cooperate with coenzyme Q10 to realize the combined antioxidant effect. Among them, lipoic acid is easily reduced to dihydrolipoic acid after entering the human body, and the cooperation of lipoic acid and coenzyme Q10 can promote the regeneration of vitamin C and vitamin E, and play an antioxidant role. The antioxidant nutrition combination capsule of the embodiment of the present invention can also increase intracellular glutathione and coenzyme Q10, and can chelate certain metal ions. Several antioxidant combinations can better optimize the oxygen free radicals in energy and substance metabolism, resist the degeneration and aging of the body, keep the body healthy and prolong life.
本发明实施例的抗氧化营养组合胶囊中的维生素B6、维生素B12、叶酸参与蛋氨酸循环的意义:血同型半胱氨酸(Hcy)是蛋氨酸代谢的中间产物,其合成代谢途径及相关酶系统(蛋氨酸合成酶、胱硫醚β合成酶)缺陷,叶酸、B12、B6缺乏均可引起高同型半胱氨酸血症。多年来的调查研究表明, 高血同型半胱氨酸促进了动脉粥样硬化的发生,参与了心脑血管疾病的发展,被认为是缺血性卒中、痴呆、的危险因素。我国平均高血同型半胱氨酸患病率为27.5%,中国人群特殊的烹饪方式,煎炸炒菜,在这种烹饪的过程中叶酸被破坏掉,导致大多数人群缺乏叶酸等维生素,长期缺乏影响能量代谢、蛋白质代谢及核酸的形成,导致高同型半胱氨酸血症,导致多种疾病的发生。我们这款饮料就是各种营养物质在能量代谢中维护人体的机能,另外在各种维生素发挥辅酶作用的同时,加强蛋氨酸的代谢途径,降低血同型半胱氨酸,使蛋氨酸代谢顺利进行,更完美的促进能量代谢及蛋白质核酸代谢,避免发生各种疾病,包括动脉硬化性心脑血管病。Significance of vitamin B6, vitamin B12, and folic acid in the antioxidant nutrition combination capsule of the embodiment of the present invention participating in the methionine cycle: blood homocysteine (Hcy) is an intermediate product of methionine metabolism, and its synthetic metabolic pathway and related enzyme system ( Methionine synthase, cystathionine β synthase) deficiency, folic acid, B12, B6 deficiency can cause hyperhomocysteinemia. Over the years, investigations and studies have shown that high blood homocysteine promotes the occurrence of atherosclerosis, participates in the development of cardiovascular and cerebrovascular diseases, and is considered to be a risk factor for ischemic stroke, dementia, and so on. The average prevalence of high blood homocysteine in China is 27.5%. The special cooking methods of the Chinese population, such as frying and stir-frying, destroy folic acid during this cooking process, resulting in the lack of folic acid and other vitamins in most people. Long-term deficiency It affects energy metabolism, protein metabolism and the formation of nucleic acid, leading to hyperhomocysteinemia and the occurrence of various diseases. Our drink is the function of various nutrients to maintain the human body during energy metabolism. In addition, when various vitamins play the role of coenzyme, it strengthens the metabolic pathway of methionine, reduces blood homocysteine, and makes methionine metabolism go smoothly. Perfectly promote energy metabolism and protein nucleic acid metabolism, avoid various diseases, including arteriosclerotic cardiovascular and cerebrovascular diseases.
通过大量的实验研究表明,蛋氨酸循环参与机体代谢机制如下:A large number of experimental studies have shown that the mechanism of methionine cycle involved in body metabolism is as follows:
(1)蛋氨酸循环与转甲基作用:含有S-甲基的蛋氨酸(甲硫氨酸),在转甲基之前必须先与ATP结合,生成S-腺苷甲硫氨酸(SAM,又称为活性甲硫氨酸),在甲基转移酶的作用下,SAM方可将甲基转移至甲基团接受器,使其甲基化,生成甲基化产物(如:胆碱),而同时SAM去甲基后转化为S-腺苷-同型半胱氨酸,再进一步脱去腺苷后生成同型半胱氨酸。同型半胱氨酸可以接受N5-甲基四氢叶酸提供的甲基,重新生产蛋氨酸(甲硫氨酸),如此便形成一个循环过程,称为蛋氨酸(甲硫氨酸)循环。催化N5-甲基四氢叶酸转甲基生成甲硫氨酸的酶称为蛋氨酸合成酶(又叫:蛋氨酸甲基转移酶,N5-甲基四氢叶酸转甲基酶),其辅酶是VB12(维生素B12),它参与甲基的转移。通过各种转甲基作用可以生产多种含甲基的重要生理活性物质,如:胆碱可进一步生成卵磷脂(促进髓鞘生成)或形成乙酰胆碱(参与神经递质恢复)。(1) Methionine cycle and transmethylation: Methionine (methionine) containing S-methyl must be combined with ATP before transmethylation to generate S-adenosylmethionine (SAM, also known as is active methionine), under the action of methyltransferase, SAM can transfer the methyl group to the methyl group acceptor, make it methylated, and generate methylated products (such as: choline), while At the same time, SAM is converted into S-adenosyl-homocysteine after demethylation, and then further adenosine is removed to generate homocysteine. Homocysteine can accept the methyl group provided by N5-methyltetrahydrofolate to regenerate methionine (methionine), thus forming a cyclic process called methionine (methionine) cycle. The enzyme that catalyzes the transmethylation of N5-methyltetrahydrofolate to generate methionine is called methionine synthase (also known as: methionine methyltransferase, N5-methyltetrahydrofolate transmethylase), and its coenzyme is VB12 (vitamin B12), which is involved in the transfer of methyl groups. A variety of important physiologically active substances containing methyl groups can be produced through various transmethylation effects, such as: choline can further generate lecithin (promote myelin production) or form acetylcholine (involved in the recovery of neurotransmitters).
(2)一碳单位循环:此外,在辅酶VB12(维生素B12)的参与下,N5-甲基四氢叶酸经过蛋氨酸转移酶作用脱甲基形成四氢叶酸,后者接受氨基酸提供的一碳单位,形成N10-甲酰四氢叶酸后再进一步生成N5,N10-甲基四氢叶酸,后者通过N5,N10-亚甲基四氢叶酸还原酶作用形成N5-甲基四氢叶酸, 形成另一个循环~“一碳单位循环”。其中,N5,N10-亚甲基四氢叶酸还原酶又是胸苷酸合酶的关键辅酶,后者在嘧啶生物合成的必须反应中可催化单磷酸脱氧鸟苷(d-UMP)转化成单磷酸脱氧胸苷(d-TMP),因而促进DNA合成与修复。(2) One-carbon unit cycle: In addition, with the participation of coenzyme VB12 (vitamin B12), N5-methyltetrahydrofolate is demethylated by methionine transferase to form tetrahydrofolate, which accepts the one-carbon unit provided by amino acids , form N10-formyltetrahydrofolate and then further generate N5, N10-methyltetrahydrofolate, which forms N5-methyltetrahydrofolate through the action of N5, N10-methylenetetrahydrofolate reductase, forming another A cycle ~ "one carbon unit cycle". Among them, N5, N10-methylenetetrahydrofolate reductase is the key coenzyme of thymidylate synthase, which can catalyze the conversion of deoxyguanosine monophosphate (d-UMP) into monophosphate in the necessary reaction of pyrimidine biosynthesis. Deoxythymidine phosphate (d-TMP), thus promoting DNA synthesis and repair.
(3)当VB12(维生素B12)缺乏时,N5-甲基四氢叶酸的甲基不能转移,这不仅不利于甲硫氨酸的生成,影响转甲基作用,影响多种生理活性的甲基化生物顺利生成;同时也影响四氢叶酸的生成,使组织中游离的四氢叶酸减少,不能重新利用它来转运一碳单位,影响嘧啶的合成,导致DNA核酸合成,影响修复。此外,当VB12(维生素B12)缺乏时,影响同型半胱氨酸甲基化生成蛋氨酸,从而引起同型半胱氨酸堆积,目前认为高同型半胱氨酸血症具有重要的病理意义,高半胱氨酸血症是动脉粥样硬化、中风、痴呆等疾病的独立风险因子。(3) When VB12 (vitamin B12) is deficient, the methyl group of N5-methyltetrahydrofolate cannot be transferred, which is not conducive to the formation of methionine, affects the transmethylation effect, and affects various physiologically active methyl groups At the same time, it also affects the production of tetrahydrofolate, reducing the free tetrahydrofolate in the tissue, which cannot be reused to transport one-carbon units, affects the synthesis of pyrimidine, leads to the synthesis of DNA nucleic acid, and affects repair. In addition, when VB12 (vitamin B12) is deficient, it will affect the methylation of homocysteine to generate methionine, thereby causing the accumulation of homocysteine. At present, it is believed that hyperhomocysteinemia has important pathological significance. Cystinemia is an independent risk factor for diseases such as atherosclerosis, stroke, and dementia.
(4)在某些组织中,如肝或肾通过反硫化过程,同型半胱氨酸在胱硫醚β合成酶的作用下转化成胱硫醚,进一步生成半胱氨酸,γ-Glu-半胱氨酸,最终形成谷胱甘肽。这一代谢途径中,维生素B6为重要辅酶。(4) In some tissues, such as liver or kidney, through the reverse sulfuration process, homocysteine is converted into cystathionine under the action of cystathionine β synthetase, and further generates cysteine, γ-Glu- cysteine, which eventually forms glutathione. In this metabolic pathway, vitamin B6 is an important coenzyme.
(5)当叶酸缺乏时,一碳单位循环受影响,核酸及蛋白质的生物合成受影响,导致疾病的发生。(5) When folic acid is deficient, the one-carbon unit cycle is affected, and the biosynthesis of nucleic acid and protein is affected, leading to the occurrence of diseases.
本发明实施例提供一种抗氧化营养组合胶囊,组合了β烟酰胺单核苷酸、辅酶Q10、维生素E、维生素C、硫辛酸等多种抗氧化剂,协同作用,互相增强抗氧化及抗衰老效果,保护全身组织细胞,是全身组织细胞保持健康年轻态,使生命更长久;同时针对于中国饮食特点的缺陷设计而成,防止因某些营养物质的缺乏导致的能量及物质代谢障碍,组合了维生素B6、维生素B12及叶酸组合,三者相互配合可以促进蛋氨酸代谢,实现人体能量代谢及物质代谢的枢纽,具有有效预防动脉硬化,使人体各种代谢健康地进行,增加了辅酶Q10具有抗氧化、抗衰老等功效,可以起到保护心脏及身体重要器官的作用,可以维持人体机能的健康状态。The embodiment of the present invention provides an antioxidant nutritional combination capsule, which combines various antioxidants such as β-nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid, etc., and synergistically enhances anti-oxidation and anti-aging The effect is to protect the tissue cells of the whole body, so that the tissue cells of the whole body can maintain a healthy and young state and make life longer; at the same time, it is designed for the defects of the Chinese diet characteristics, preventing energy and material metabolism disorders caused by the lack of certain nutrients. The combination of vitamin B6, vitamin B12 and folic acid can promote the metabolism of methionine and realize the hub of human energy metabolism and material metabolism. It can effectively prevent arteriosclerosis and make various metabolisms of the human body go on healthily. Oxidation, anti-aging and other effects can protect the heart and vital organs of the body, and can maintain the health of human body functions.
本发明实施例的抗氧化营养组合胶囊扩大了现有产品的抗氧化制剂的种类,加强了抗氧化作用。其组合了β烟酰胺单核苷酸、辅酶Q10、维生素E、维生素C、硫辛酸等多种抗氧化剂,协同作用,互相增强抗氧化及抗衰老效果,保护全身组织细胞,是全身组织细胞保持健康年轻态,使生命更长久。而且,本发明实施例的抗氧化营养组合胶囊针对于中国饮食特点的缺陷设计而成,防止因某些营养物质的缺乏导致的能量及物质代谢障碍,组合了维生素B6、维生素B12及叶酸组合,对于促进蛋氨酸代谢,有效预防动脉硬化,使人体各种代谢健康地进行。本发明实施例的抗氧化营养组合胶囊增加多种维生素,促进机体的能量代谢及物质代谢更加全面。本发明实施例的抗氧化营养组合胶囊促进蛋氨酸代谢途径,更好的协调蛋白质代谢、核酸代谢及能量代谢,预防多种代谢疾病,减轻人体全身动脉硬化。本发明实施例的抗氧化营养组合胶囊加入多种抗氧化制剂,协同作用,互相增强,具有抗氧化,抗衰老,保护组织细胞的作用,同时具有调整代谢,抗肿瘤作用,使机体更健康,更长寿。The anti-oxidation nutrition combination capsule of the embodiment of the present invention expands the types of anti-oxidation preparations of existing products and strengthens the anti-oxidation effect. It combines multiple antioxidants such as β-nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid, etc., synergistically enhances the anti-oxidation and anti-aging effects, protects the tissue cells of the whole body, and is the maintenance of the tissue cells of the whole body. A healthy and youthful state makes life longer. Moreover, the anti-oxidant nutritional combination capsule of the embodiment of the present invention is designed for the defects of the Chinese diet characteristics, to prevent energy and substance metabolism disorders caused by the lack of certain nutrients, combined with vitamin B6, vitamin B12 and folic acid, It promotes the metabolism of methionine, effectively prevents arteriosclerosis, and makes various metabolisms of the human body go on healthily. The anti-oxidation nutritional combination capsule of the embodiment of the present invention adds multiple vitamins to promote more comprehensive energy metabolism and substance metabolism of the body. The anti-oxidation nutritional combination capsule of the embodiment of the present invention promotes the methionine metabolism pathway, better coordinates protein metabolism, nucleic acid metabolism and energy metabolism, prevents various metabolic diseases, and alleviates arteriosclerosis throughout the human body. The anti-oxidation nutritional combination capsule of the embodiment of the present invention is added with various anti-oxidation preparations, synergistically, mutually reinforcing, has the functions of anti-oxidation, anti-aging, and protecting tissue cells, and at the same time has the functions of regulating metabolism and anti-tumor, making the body healthier, live longer.
显然,本领域的技术人员可以对本发明实施例进行各种改动和变型而不脱离本发明实施例的精神和范围。这样,倘若本发明实施例的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。Apparently, those skilled in the art can make various changes and modifications to the embodiments of the present invention without departing from the spirit and scope of the embodiments of the present invention. Thus, if the modifications and variations of the embodiments of the present invention fall within the scope of the claims of the present invention and equivalent technologies, the present invention also intends to include these modifications and variations.
Claims (7)
- 一种抗氧化营养组合胶囊,其特征在于,每粒所述抗氧化营养组合胶囊中含有150~900mg的β-烟酰胺单核苷酸、10~50mg的辅酶Q10、50~500mg的维生素E、100~1000mg的维生素C、50~300mg的硫辛酸、0.4~5mg维生素B6、10~100ug的维生素B12和20~200ug叶酸;所述抗氧化营养组合胶囊平均粒重为0.5g,所述抗氧化营养组合胶囊的内容物平均体积为0.68mL。An antioxidant nutritional combination capsule, characterized in that each of the antioxidant nutritional combination capsules contains 150-900 mg of β-nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000mg of vitamin C, 50-300mg of lipoic acid, 0.4-5mg of vitamin B6, 10-100ug of vitamin B12 and 20-200ug of folic acid; the average grain weight of the antioxidant nutrition combination capsule is 0.5g, and the antioxidant The average volume of the contents of the nutritional combination capsules is 0.68 mL.
- 根据权利要求1所述的抗氧化营养组合胶囊,其特征在于,所述维生素B6、所述维生素B12、所述叶酸相互配合以促进蛋氨酸循环。The antioxidant nutritional combination capsule according to claim 1, wherein the vitamin B6, the vitamin B12, and the folic acid cooperate with each other to promote the circulation of methionine.
- 根据权利要求1或2所述的抗氧化营养组合胶囊,其特征在于,所述维生素E是一种脂溶性维生素,所述维生素E的水解产物为生育酚,所述维生素C是一种多羟基化合物,所述维生素B6包括吡哆醇、吡哆醛和吡哆胺。The antioxidant nutritional combination capsule according to claim 1 or 2, wherein the vitamin E is a fat-soluble vitamin, the hydrolyzate of vitamin E is tocopherol, and the vitamin C is a polyhydroxy Compounds, the vitamin B6 includes pyridoxine, pyridoxal and pyridoxamine.
- 根据权利要求1所述的抗氧化营养组合胶囊,其特征在于,每粒所述抗氧化营养组合胶囊中还含有明胶、甘油、水和焦糖色素。The antioxidant nutrition combination capsule according to claim 1, characterized in that, each of the antioxidant nutrition combination capsules also contains gelatin, glycerin, water and caramel pigment.
- 根据权利要求1~4任一项所述的抗氧化营养组合胶囊,其特征在于,每粒所述抗氧化营养组合胶囊中含有200mg的β-烟酰胺单核苷酸、40mg的辅酶Q10、50mg的维生素E、100mg的维生素C、50mg的硫辛酸、5mg维生素B6、100ug的维生素B12和200ug叶酸。The antioxidant nutrition combination capsule according to any one of claims 1 to 4, characterized in that each of the antioxidant nutrition combination capsules contains 200 mg of β-nicotinamide mononucleotide, 40 mg of coenzyme Q10, and 50 mg of 100mg of vitamin E, 100mg of vitamin C, 50mg of lipoic acid, 5mg of vitamin B6, 100ug of vitamin B12 and 200ug of folic acid.
- 根据权利要求5所述的抗氧化营养组合胶囊,其特征在于,所述β-烟酰胺单核苷酸、所述辅酶Q10、所述维生素E、所述维生素C和所述硫辛酸相互配合且协同作用形成抗氧化组合。The antioxidant nutritional combination capsule according to claim 5, wherein the β-nicotinamide mononucleotide, the coenzyme Q10, the vitamin E, the vitamin C and the lipoic acid cooperate with each other and Working synergistically to form an antioxidant combination.
- 根据权利要求6所述的抗氧化营养组合胶囊,其特征在于,所述维生素E、所述维生素C和所述硫辛酸协同所述辅酶Q10实现联合抗氧化作用。The antioxidant nutritional combination capsule according to claim 6, wherein the vitamin E, the vitamin C and the lipoic acid cooperate with the coenzyme Q10 to achieve a combined antioxidant effect.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/109295 WO2023004690A1 (en) | 2021-07-29 | 2021-07-29 | Antioxidant nutrition composition capsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/109295 WO2023004690A1 (en) | 2021-07-29 | 2021-07-29 | Antioxidant nutrition composition capsule |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023004690A1 true WO2023004690A1 (en) | 2023-02-02 |
Family
ID=85085992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/109295 WO2023004690A1 (en) | 2021-07-29 | 2021-07-29 | Antioxidant nutrition composition capsule |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023004690A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102150861A (en) * | 2011-02-15 | 2011-08-17 | 辽宁盛生医药集团有限公司 | Nutritional supplement with functions of oxidation resistance and fatigue resistance |
CN102440386A (en) * | 2010-10-15 | 2012-05-09 | 胥永贵 | Full composite human body antioxidant |
CN105878277A (en) * | 2016-02-29 | 2016-08-24 | 孙文觉 | Oral vitamin capsules for promoting hair growth and beautifying hair |
CN111035012A (en) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | Antioxidant nutrition combination capsule and preparation method thereof |
-
2021
- 2021-07-29 WO PCT/CN2021/109295 patent/WO2023004690A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102440386A (en) * | 2010-10-15 | 2012-05-09 | 胥永贵 | Full composite human body antioxidant |
CN102150861A (en) * | 2011-02-15 | 2011-08-17 | 辽宁盛生医药集团有限公司 | Nutritional supplement with functions of oxidation resistance and fatigue resistance |
CN105878277A (en) * | 2016-02-29 | 2016-08-24 | 孙文觉 | Oral vitamin capsules for promoting hair growth and beautifying hair |
CN111035012A (en) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | Antioxidant nutrition combination capsule and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
ZHOU KAIGUO, HE GUI-ZHEN, ZHANG RUI: "Vitamins:updates on current research", CHINESE JOURNAL OF PRACTICAL INTERNAL MEDICINE, vol. 31, no. 5, 31 May 2011 (2011-05-31), pages 381 - 383, XP093028737, ISSN: 1005-2194 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111035012A (en) | Antioxidant nutrition combination capsule and preparation method thereof | |
US6660293B2 (en) | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects | |
US20060115556A1 (en) | Nutritional supplement drink containing xanthone extracts | |
US20070026109A1 (en) | Nutritional supplements containing xanthone extracts | |
US20060269616A1 (en) | Supplement composition and method of use for enhancement of DNA repair process | |
RU2663017C2 (en) | Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health | |
JP2008516948A (en) | Methods and compositions for supplementation of nutritional deficiencies in kidney patients | |
CN109045037A (en) | It is a kind of to promote the anti-apolexis composition of cozymase, preparation and preparation method thereof | |
Gonzalez et al. | Mitochondrial correction: a new therapeutic paradigm for cancer and degenerative diseases | |
WO2001056572A1 (en) | Compositions and methods for promoting healthy joints | |
Lachance | Overview of key nutrients: micronutrient aspects | |
GB2585619A (en) | A supplement | |
JP5931324B2 (en) | Composition for reducing oxidative stress and / or side effects caused during cancer chemotherapy or improving nutritional status during cancer chemotherapy | |
WO2023004690A1 (en) | Antioxidant nutrition composition capsule | |
EP3043788B1 (en) | D-glyceric acid or dl-glyceric acid for use in the treatment of degeneration diseases related to aging | |
CN113615833A (en) | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof | |
CA2291959A1 (en) | A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses | |
Vasam et al. | Nutritional regulation of mitochondrial function | |
Alturfan | Water-soluble vitamins | |
Rivlin | Vitamin Defi ciencies | |
CN110692878A (en) | Health-care and nutritional functional beverage | |
Marks | Biological functions of vitamins | |
Gao-Balch | Reconsidered B-vitamins play a vital role in maintaining good health and well-being | |
Kucharská | Vitamins in mitochondrial function | |
Wiss et al. | The liver and vitamins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21951297 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21951297 Country of ref document: EP Kind code of ref document: A1 |